Blood and Urine Biomarkers in Age-Related Macular Degeneration: Current Understanding and Future Directions

I. Executive Summary

Age-related macular degeneration (AMD) represents a leading cause of central vision impairment globally, affecting millions of middle-aged and older individuals. This progressive degenerative disease can lead to permanent damage to central vision, significantly impacting an individual's physical and mental well-being. Clinically, AMD is categorized into early, intermediate, and late stages, with the late stage further differentiated into dry (geographic atrophy, GA) and wet (neovascular AMD, nAMD) forms. While current diagnostic approaches predominantly rely on ophthalmic examinations and advanced imaging modalities such as Optical Coherence Tomography (OCT), the early symptoms of AMD are often subtle and difficult to detect, highlighting a critical need for non-invasive and highly sensitive biomarkers for early identification.   

Extensive research has identified numerous blood and urine biomarkers associated with AMD pathogenesis. These markers primarily reflect underlying biological processes, including lipid metabolism, systemic inflammation, and genetic predispositions. In blood, notable examples include C-reactive protein (CRP), various lipid profiles such as High-Density Lipoprotein Cholesterol (HDL-C), Low-Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG), as well as composite inflammatory indices like the Red Blood Cell Distribution Width/Albumin Ratio (RAR).From urine, specific inflammatory cytokines, such as Transforming Growth Factor-β1 (TGF-β1) and Macrophage Chemoattractant Protein-1 (MCP-1), have also demonstrated associations with early AMD. 

Despite these promising associations and the mechanistic understandings they provide, the widespread adoption of these biomarkers for routine clinical applications—including screening, definitive diagnosis, prognosis, or guiding therapeutic interventions in AMD patients—remains largely unrealized. This translational gap is attributed to significant challenges, including inherent inconsistencies in research findings, a critical lack of assay standardization, and the overarching need for robust, large-scale validation studies to conclusively demonstrate their clinical efficacy and impact on patient outcomes.

The future landscape of AMD biomarker discovery is being profoundly shaped by advancements in multi-omics integration, the burgeoning field of liquid biopsies, and the transformative application of Artificial Intelligence (AI) and machine learning. These cutting-edge approaches are anticipated to accelerate the identification and validation of more precise and personalized biomarkers, ultimately paving the way for more effective AMD prevention and management strategies. 

II. Introduction to Age-Related Macular Degeneration (AMD)

Overview of AMD: Disease Forms and Stages

Age-related macular degeneration (AMD) is a progressive neurodegenerative disorder and stands as the leading cause of irreversible central vision loss in developed countries, affecting millions worldwide. The profound impact of AMD extends beyond visual impairment, significantly affecting patients' physical and mental well-being due to the loss of central vision crucial for daily activities. 

The clinical progression of AMD is systematically stratified into three principal stages: early, intermediate, and late AMD. Each stage is characterized by distinct pathological features and visual implications.  

• Early AMD: This initial stage is characterized by the presence of small to medium-sized drusen, which are extracellular waste material deposits that accumulate beneath the retina. At this stage, patients typically experience minimal or no noticeable impact on their central vision, making early detection challenging without specialized examination.
• Intermediate AMD: This stage is defined by the presence of larger drusen, pigmentary abnormalities within the retina, or a combination of medium drusen with pigmentary changes. Patients may begin to notice some subtle changes in their central vision, such as blurriness or distortion, but progression to the more severe late AMD is often slow and not inevitable. This stage is particularly crucial as it carries a significant risk of progression to the vision-threatening late AMD, with an estimated rate of approximately 27% over five years.  
• Late AMD: This represents the advanced, vision-impairing stage, which manifests in two distinct forms :  
  • Dry (Atrophic) AMD, also known as Geographic Atrophy (GA): This form involves the gradual degeneration and death (atrophy) of retinal cells, including photoreceptors and the retinal pigment epithelium (RPE). This cellular loss leads to clearly demarcated areas of missing retina and progressive central vision loss. GA accounts for approximately one-third of all late-stage AMD cases.
    
  • Wet (Neovascular) AMD (nAMD): Considered the more aggressive form, nAMD is characterized by the growth of abnormal, fragile blood vessels, known as choroidal neovascularization (CNV), beneath the retina. These newly formed vessels are prone to leakage of fluid and blood, which damages the macula and often results in sudden and severe central vision loss. This form is responsible for approximately 80% of the severe vision impairment associated with AMD.  

It is important to note that AMD can affect one eye or both eyes differently, with each eye potentially being at a different stage of the disease.

The Role of Biomarkers in AMD Management

Biomarkers are objectively measurable characteristics—cellular, biochemical, or molecular alterations detectable in biological samples—that serve as indicators of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions. They can be specific cells, molecules, genes, gene products, enzymes, or hormones.  

In the context of AMD, biomarkers are indispensable tools poised to revolutionize disease management. They hold the potential to predict disease incidence, facilitating the identification of at-risk individuals even before clinical symptoms manifest. By elucidating the complex pathophysiological etiologies underlying AMD, biomarkers can guide screening protocols and aid in early and definitive diagnosis, which is particularly critical given the insidious nature of early AMD. Furthermore, biomarkers can provide crucial prognostic information, forecasting the likely course and severity of the disease, and enabling the monitoring of disease progression over time. They are also vital for assessing the efficacy of therapeutic interventions, allowing for timely adjustments to treatment plans. Beyond direct clinical applications, biomarkers are essential for identifying novel drug targets and advancing personalized medicine strategies, tailoring treatments to individual patient profiles. 

Rationale for Blood and Urine Biomarkers

A significant challenge in AMD management is the often-inconspicuous nature of early AMD symptoms, making their detection difficult through conventional ophthalmic examinations alone. This diagnostic gap necessitates the development of more sensitive, accessible, and non-invasive tools. 

Blood and urine samples offer a compelling advantage as sources for biomarkers due to their non-invasive collection methods, relative ease of acquisition, and cost-effectiveness when compared to more invasive procedures such as ocular fluid biopsies or tissue biopsies. This accessibility allows for repeated sampling, which is crucial for monitoring chronic conditions like AMD.  

AMD is increasingly recognized as a systemic condition, with substantial evidence linking it to chronic low-grade inflammation and dysregulated lipid metabolism. Blood and urine, as systemic biofluids, are uniquely positioned to reflect these broader physiological changes associated with AMD, providing a window into the systemic burden of the disease.   

Furthermore, the eye and kidney exhibit striking similarities in their structural, developmental, physiological, and pathogenic pathways. For instance, both organs possess intricate vascular networks (glomerulus in kidney, choroid in eye) and share common hormonal cascades, such as the renin–angiotensin–aldosterone system. This anatomical and functional parallelism lends additional weight to the potential of urine as a valuable clinical specimen for uncovering unique biomarker profiles relevant to AMD, potentially reflecting mild abnormalities in renal function that are part of the systemic manifestation of AMD. 

III. Blood Biomarkers for Age-Related Macular Degeneration

Blood-based biomarkers offer a convenient and relatively non-invasive approach to assess systemic factors contributing to AMD. Research has identified several categories of blood biomarkers, including inflammatory, lipid metabolism, and genetic markers, each providing unique insights into the disease's complex pathogenesis.

A. Inflammatory Markers

A substantial body of evidence underscores the strong association between systemic inflammation and AMD, with inflammation playing a critical role in accelerating disease progression through mechanisms such as oxidative stress, complement activation, and the release of pro-inflammatory cytokines. 

• C-reactive protein (CRP): CRP is a widely recognized, albeit non-specific, serum marker indicative of subclinical inflammation. Elevated CRP levels are consistently identified as a significant risk factor for AMD, particularly correlating with intermediate and advanced stages of the disease. Higher plasma CRP levels are notably associated with AMD prevalence. A comprehensive Mendelian Randomization (MR) and National Health and Nutrition Examination Survey (NHANES) study explicitly identified CRP as a risk factor for AMD development, with its prognostic significance becoming more pronounced in the late stages of the disease. This study also revealed a U-shaped nonlinear relationship between CRP and AMD risk, where levels above 6.5 mg/dL were associated with a sharp increase in AMD prevalence, highlighting the critical role of inflammatory responses in advanced disease. 

  • The observation that lipid metabolism-related biomarkers show stronger associations with early AMD, whereas CRP's significance is pronounced in late AMD , suggests a dynamic and evolving pathological landscape in AMD. In the early stages, where drusen accumulation (a lipid-rich deposit) is a hallmark, dysregulation of lipid metabolism appears to be a more dominant and measurable driver of disease. As the disease progresses to its late, vision-threatening forms, systemic inflammation, as reflected by markers like CRP, becomes a more prominent and influential factor. This progression in the dominant pathological mechanism implies that effective diagnostic and therapeutic strategies for AMD may need to be stage-specific, targeting the most active and impactful pathophysiological processes at each phase of the disease. This dynamic understanding can inform the development of precision medicine approaches, ensuring interventions are tailored to the prevailing biological drivers. 

• Red Blood Cell Distribution Width/Albumin Ratio (RAR): RAR is an innovative composite biomarker that integrates measures of both inflammation (Red Blood Cell Distribution Width, RDW) and nutritional status (serum albumin). Elevated RDW, reflecting variability in red blood cell volume, is linked to retinal vascular occlusive diseases associated with inflammation, oxidative stress, and endothelial dysfunction. Low serum albumin, on the other hand, is a marker of poor prognosis in various inflammatory conditions. A recent study found a positive linear correlation between RAR and the odds of AMD prevalence in United States adults.Specifically, each unit increase in RAR corresponded to a 30% increase in the odds of AMD prevalence, and the highest quintile of RAR values showed 1.7 times greater odds of AMD prevalence compared to the lowest quintile. 

• Neutrophils and Other Inflammatory Biomarkers: Research has demonstrated a significant association between the absolute number of neutrophils in peripheral blood and the severity of AMD. This finding reinforces the direct involvement of immune cells in disease progression. Beyond absolute cell counts, various complete blood count (CBC)-derived inflammation indices, such as the Neutrophil-to-Lymphocyte Ratio (NLR), Monocyte-to-Lymphocyte Ratio (MLR), Platelet-to-Lymphocyte Ratio (PLR), and Systemic Immune-Inflammation Index (SII), have shown utility in other chronic inflammatory conditions, including diabetes complications and cardiovascular diseases. Their potential relevance in AMD, particularly in the context of retinal microvascular damage, is an active area of investigation. Interleukin-6 (IL-6) and Interleukin-8 (IL-8) are also under investigation as systemic inflammatory mediators in AMD. Notably, elevated IL-6 levels are significantly associated with late AMD, encompassing both Geographic Atrophy (GA) and neovascular AMD (nAMD). 

B. Lipid Metabolism Markers

Lipid metabolism, alongside systemic inflammation, is increasingly recognized as having a causal relationship with the onset and progression of AMD. The formation of drusen, a defining clinical feature of early AMD, is directly linked to dysregulated lipid metabolism.

• Triglycerides (TG): Mendelian Randomization (MR) analysis consistently identified a significant negative causal relationship between TG levels and AMD development, suggesting a protective role. NHANES data corroborated these findings, showing significantly lower TG levels in AMD patients, with the lowest concentrations observed in the late AMD group. This protective effect was evident across different AMD subtypes, with significant negative causal relationships observed in dry AMD, wet AMD, and early-stage AMD.
• High-density lipoprotein cholesterol (HDL-C): In contrast to TG, MR analysis identified HDL-C as a significant risk factor for AMD development, showing a positive causal relationship. NHANES data confirmed higher HDL-C levels in AMD patients, reaching their highest concentrations in the late AMD group. HDL-C also demonstrated a significant causal relationship with early-stage AMD.  
• Low-density lipoprotein cholesterol (LDL-C): Previous studies indicate that lower levels of LDL-C are linked to an increased risk for AMD. MR analysis showed a significant negative causal relationship in dry AMD, suggesting a potential protective effect, although this association did not remain significant after False Discovery Rate (FDR) correction. 
• Apolipoproteins (ApoA1, ApoB): Research suggests that higher levels of apolipoprotein A1 (ApoA1) increase the risk for all types of AMD, while lower levels of apolipoprotein B (ApoB) are linked to AMD. MR analysis found significant causal relationships with early-stage AMD, with ApoA1 associated with increased risk and ApoB with reduced risk.  
• Serum Cholesterol: Beyond specific lipoproteins, studies have reported increased LDL and decreased HDL levels in patients with late-stage dry and wet AMD. Overall, higher total cholesterol levels have been significantly associated with an increased AMD risk. 
  • The consistent and nuanced findings from multiple studies linking various lipid markers (TG, HDL-C, LDL-C, apolipoproteins) to AMD, particularly in its early stages, provides a crucial understanding. This reinforces the concept that AMD is not merely a localized ocular pathology but is intricately connected to broader systemic metabolic health. The direct relationship between early AMD features, such as drusen, and lipid metabolism further solidifies this link. This suggests that systemic interventions targeting lipid profiles, such as dietary modifications or pharmacological management, could serve as important preventative or disease-modifying strategies for AMD, especially in its nascent stages, highlighting a promising avenue for integrated patient care. 

C. Other Systemic Blood Markers

• Homocysteine: Elevated homocysteine levels are believed to be associated with advanced AMD, with particularly higher concentrations observed in neovascular AMD. However, the evidence for homocysteine as a viable biomarker remains controversial, primarily due to the small cohort sizes and resulting low statistical power in many studies. 
• Interferon γ-Inducible Protein 10 (IP-10) and Eotaxin: These chemokines have been suggested as promising serum biomarkers for early AMD detection. Patients in early AMD stages have demonstrated significantly higher levels of both IP-10 and eotaxin compared to healthy controls. Intriguingly, eotaxin-2 (CCL24) levels were found to be significantly elevated in wet AMD patients even after anti-VEGF treatment, suggesting a potential role in choroidal neovascularization (CNV) that operates independently of the VEGF pathway. 
• Vascular Endothelial Growth Factor (VEGF): Elevated plasma VEGF levels are frequently observed in AMD patients compared to healthy controls, with significantly higher levels in wet AMD than in dry AMD, underscoring its pivotal role in disease progression and the development of neovascularization. The advent of anti-VEGF therapies has revolutionized the management of nAMD, effectively reducing blood and fluid leakage and helping to preserve visual acuity. 
• Soluble FMS-like Tyrosine Kinase-1 (sFlt-1) / soluble vascular endothelial growth factor receptor-1 (sVEGFR-1): sFlt-1 has been identified as a promising novel biomarker for AMD. Significantly lower sFlt-1 levels have been observed in patients with nvAMD compared to those with early AMD or no AMD. For individuals over 73 years of age, sFlt-1 levels below 80 pg/ml were associated with a remarkable 6.7-fold increased risk of nvAMD, positioning it as one of the strongest associated serum biomarkers for nvAMD to date.Consequently, monitoring sFlt-1 levels holds potential for identifying patients at high risk for progression to nvAMD. 
• MicroRNAs (miRNAs): miRNAs are small, single-stranded non-coding RNA molecules that regulate gene expression at the post-transcriptional level. They are remarkably stable in various body fluids, including serum.Several miRNAs are emerging as potential biomarkers for AMD due to their dysregulation in key pathological processes such as inflammation, pathological angiogenesis, and oxidative stress. Examples of frequently identified dysregulated miRNAs include miR-27a, miR-146a, miR-23a, miR-34a, miR-126, and miR-155.Beyond their diagnostic and prognostic potential, miRNAs are also considered promising therapeutic targets for AMD. 
  • The identification of such a diverse array of blood biomarkers—ranging from general inflammatory markers (homocysteine, IP-10, eotaxin) to specific growth factors (VEGF, sFlt-1) and intricate genetic regulators (miRNAs)—provides a crucial understanding. This highlights that AMD's systemic involvement is not confined to a single biological pathway or mechanism. Instead, it represents a complex interplay of various interconnected processes, including chronic inflammation, aberrant angiogenesis, and dysregulated cellular functions. This inherent complexity strongly suggests that a single, standalone biomarker is unlikely to provide a comprehensive assessment of AMD. Rather, the future of AMD diagnostics and prognostics will likely rely on the development and validation of multi-biomarker panels that can capture these different, yet interconnected, facets of the disease, offering a more complete picture of its systemic burden and progression.

D. Genetic Biomarkers (Blood-based)

Age-related macular degeneration is a multifactorial disease, with a significant interplay between genetic predispositions and environmental influences. Genetic variants are estimated to account for approximately 70% of the overall risk for AMD.

• Key Genetic Loci and Genes:

  • Complement Pathway Genes: Common and rare variants within genes of the complement pathway, particularly Complement Factor H (CFH), along with C2, C3, CFB, and CFI, are recognized as significant genetic risk factors for AMD. It is noteworthy that C-reactive protein (CRP) has been shown to interfere with the regulatory function of CFH, thereby indirectly activating inflammatory pathways and increasing AMD susceptibility. 
  • ARMS2 and HTRA1: Variants located in the 10q26 chromosomal region, specifically within the ARMS2 and HTRA1 genes, are major genetic contributors to AMD risk. The strong linkage disequilibrium between specific single nucleotide polymorphisms (SNPs) in these genes (e.g., rs10490924 in ARMS2 and rs11200638 in HTRA1) makes it challenging to differentiate their individual effects on AMD risk.However, the TT genotype of ARMS2/HTRA1 (rs10490924) has been shown to increase the risk of late AMD tenfold, and carriers of a risk haplotype at ARMS2/HTRA1 tend to progress to advanced disease earlier. 
  • Lipid Pathway Genes: Genes influencing high-density lipoprotein (HDL) cholesterol pathways, such as CETP and LIPC, and potentially LPL and ABCA1, have been linked to AMD based on large-scale genome-wide association studies. 
  • Other Associated Pathways: Genetic loci associated with other biological pathways, including collagen matrix (COL10A1, COL8A1), extracellular matrix (TIMP3, FBN2), DNA repair (RAD51B), and angiogenesis (VEGFA), have also been found to be associated with AMD onset, progression, and bilateral involvement.
     

• Genetic Testing for Risk Prediction:

  • Commercial genetic tests aim to predict the risk of developing advanced AMD or guide treatment. For instance, Macula Risk PGx® utilizes patient clinical information (age, BMI, smoking history, education) combined with genotypes for 15 genetic markers across 12 AMD-associated genes within an algorithm.This test is designed to identify Caucasians at high risk for progression from early or intermediate AMD to advanced forms, and its manufacturer reports a 10-year predictive accuracy of 89.5%, with both sensitivity and specificity exceeding 80%. 
  • Another test, RetnaGene™ AMD, assesses the impact of 12 genetic variants (SNPs) located on genes associated with progression to advanced wet AMD (e.g., CFH/CFH region, C2, CRFB, ARMS2, C3), integrating phenotype, age, and smoking history. However, data regarding its predictive accuracy in peer-reviewed literature was not identified in the provided documents. 

• Accuracy of Prediction Models: Predictive models that integrate genetic, epidemiologic, and clinical factors generally yield high Area Under the Curve (AUC) values, ranging from approximately 0.8 to 0.92, for predicting AMD progression. For example, one study showed an AUC of 0.92 for a model including clinical, genetic, and lifestyle factors at five years.

  • While genetic testing for AMD demonstrates impressive predictive accuracy for disease risk and progression , a critical consideration emerges from the explicit statement that these models "do not demonstrate how genetic test results alter treatment decisions or improve overall health outcomes".Furthermore, the American Academy of Ophthalmology currently recommends against routine genetic testing for AMD outside of research settings. This reveals a significant disconnect: the scientific ability to predict risk does not automatically translate into tangible clinical utility or improved patient outcomes. This suggests that future research and development efforts must transcend mere association studies. They must rigorously focus on demonstrating how biomarker-guided interventions—whether preventative, diagnostic, or therapeutic—lead to measurable and clinically meaningful benefits for patients, thereby justifying their integration into routine practice and overcoming the current recommendations against widespread use. 

Table 1: Key Blood Biomarkers for AMD and their Associations

IV. Urine Biomarkers for Age-Related Macular Degeneration

Urine presents an appealing source for biomarker discovery due to its non-invasive collection, relative abundance, and inherent stability, making it a practical biofluid for repeated sampling. Furthermore, the established structural and pathogenic similarities between the eye and the kidney suggest that urine could reflect systemic changes pertinent to AMD.  

A. Metabolomic Profiles

Untargeted urine metabolomics, often employing advanced techniques such as mass spectrometry (MS) and orthogonal partial least squares-discriminant analysis (OPLS-DA), is utilized to identify and analyze metabolic differences between AMD patients and controls, as well as across different disease stages. 

• Findings: One comprehensive study reported that, when comparing AMD patients as a collective group to healthy controls, no statistically significant differences in overall urine metabolite profiles were observed.However, when the analysis focused on disease severity, six specific urinary metabolites demonstrated significant differences (p < 0.01) across various AMD stages. Notably, two of these identified metabolites, sphingosine and phosphoethanolamine, were also found to be differentially expressed in the plasma of AMD patients compared to controls and across severity stages, suggesting their systemic relevance. Sphingosine, a sphingolipid, is particularly relevant as it participates in apoptosis and induces cell death in response to oxidative stress, a well-established central pathophysiological mechanism in AMD.  
  • The contrasting findings for urine metabolomics—where specific metabolites show stage-dependent differences, but overall distinction from controls is weak, especially when compared to the stronger signals from plasma metabolomics —provides a crucial understanding. This suggests that different biofluids may capture distinct, complementary aspects of AMD pathology. Plasma, being a direct reflection of systemic circulation, might provide a broader overview of metabolic and inflammatory dysregulation. Urine, while non-invasive, might be more indicative of specific renal-linked processes or metabolites that are actively filtered and excreted, which may or may not directly correlate with the overall systemic burden of AMD. This implies that a thoughtful strategy for biomarker discovery should consider the unique information content of each biofluid, rather than assuming one is universally superior, reinforcing the value of a multi-biofluid approach to gain a complete pathological picture. 

B. Proteomic Markers

Urinary proteomics has emerged as a highly attractive field for disease biomarker discovery. Urine contains a rich array of proteins, originating from both systemic circulation and local urogenital epithelium, making it a valuable source of diagnostic information. 

• Specific Proteins/Cytokines: Studies have specifically investigated the associations of AMD with urinary proinflammatory cytokines, including Transforming Growth Factor-β1 (TGF-β1), Macrophage Chemoattractant Protein-1 (MCP-1), and C3a-desArg, as potential non-invasive biomarkers for monitoring AMD. These markers are implicated in inflammatory responses and tissue injury, both relevant to AMD.Elevated urinary TGF-β1 levels demonstrated a significant association with early AMD, with a 24% increased odds for early AMD per 10 ng/mmol increase. Similarly, elevated urinary MCP-1 levels showed significant associations with both early AMD and geographic atrophy (GA). 
  • A noteworthy finding is the absence of a correlation between urinary and serum cytokine levels for these specific markers. This suggests that while AMD is a systemic inflammatory disease, its pathological processes might induce specific, localized inflammatory responses in distant organs (like the kidney, given the eye-kidney similarities) that are uniquely detectable in urine. This implies that urine biomarkers could offer distinct, complementary understandings into specific inflammatory pathways or disease components that are not readily captured by blood tests, reinforcing the strategic value of a multi-biofluid approach for a comprehensive understanding of AMD's systemic impact. 

C. MicroRNAs (miRNAs)

MicroRNAs (miRNAs) are small, stable non-coding RNA molecules that play crucial roles in gene regulation and can be isolated from various body fluids, including urine. Their stability in biofluids makes them attractive candidates for non-invasive biomarker development. 

• Potential: While the provided research primarily details the identification and potential of miRNAs as biomarkers in blood samples for AMD , the broader concept of liquid biopsies (which encompasses urine) strongly suggests their potential utility in urine as well. The successful exploration of urinary miRNAs for other non-renal conditions, such as respiratory diseases, further supports this potential avenue for AMD.
  • The relative paucity of specific findings on urine miRNAs for AMD, contrasted with their established presence and potential in blood and their successful application in urine for other diseases , points to a significant untapped research potential. The inherent advantages of urine collection (non-invasive, abundant volume) combined with the stability of miRNAs suggest that focused research in this area could yield novel, easily accessible AMD biomarkers. This implies that future research should not only explore the discovery of novel miRNAs in urine but also conduct rigorous cross-biofluid comparisons to determine if certain miRNA signatures are unique to urine, shared with blood, or offer complementary information, thereby maximizing their diagnostic and prognostic value. 
    
    

Table 2: Potential Urine Biomarkers for AMD

V. Clinical Utility and Stage-Specific Relevance of Blood and Urine Biomarkers

The application of blood and urine biomarkers in AMD management spans various clinical objectives, from early detection to guiding treatment. The relevance of specific biomarkers often varies depending on the stage of the disease.

A. Early Detection and Diagnosis

The early stages of AMD, whether dry or wet, are notoriously inconspicuous, making timely detection challenging through conventional ophthalmic examinations alone. Current diagnostic methods typically involve routine eye exams, Amsler grids, fluorescein angiography (FFA), and Optical Coherence Tomography (OCT). The development of non-invasive biomarkers for early detection is thus a high priority.  

• Blood Biomarkers with Early Detection Potential:
  • Lipid Metabolism Markers: A comprehensive Mendelian Randomization (MR) and NHANES study revealed that lipid metabolism-related biomarkers, including Triglycerides (TG), HDL-C, ApoA1, and ApoB, exhibit stronger associations and causal relationships with early AMD. This finding aligns with the understanding that drusen, the primary clinical feature of early AMD, are directly related to dysregulated lipid metabolism.  
  • Inflammatory Markers: Serum levels of Interferon γ-Inducible Protein 10 (IP-10) and Eotaxin have been suggested as potential biomarkers for early AMD detection, with significantly higher concentrations observed in patients with early AMD stages compared to controls. 
  • Red Blood Cell Distribution Width/Albumin Ratio (RAR): The observed positive linear correlation between RAR and AMD prevalence suggests its potential utility in identifying individuals at risk or with early disease. 
• Urine Biomarkers with Early Detection Potential:
  • Elevated urinary Transforming Growth Factor-β1 (TGF-β1) and Macrophage Chemoattractant Protein-1 (MCP-1) levels have demonstrated significant associations with early AMD, suggesting their potential as non-invasive tools for early detection.  
• Limitations: Despite these promising associations, it is crucial to note that no blood or urine biomarker has yet received approval for routine clinical use in early AMD detection. Their use remains largely confined to research settings. 
  • The repeated emphasis on the "inconspicuous" nature of early AMD symptoms coupled with the identification of several biomarkers showing stronger associations with this stage (lipid markers, IP-10, eotaxin, urinary TGF-β1/MCP-1) highlights a critical unmet clinical need. The ability to detect AMD during its asymptomatic, early phase is paramount because it offers a window for proactive interventions, potentially slowing disease progression and preserving vision before irreversible structural damage occurs. This suggests that future research must prioritize enhancing the sensitivity and specificity of these early-stage biomarkers, potentially by combining them into multi-marker panels, to develop effective, non-invasive screening tools that can identify at-risk individuals and facilitate timely clinical management.

B. Prognosis and Risk Stratification

Biomarkers serve as valuable tools for predicting the likelihood of an individual developing a certain disease or forecasting the probable course and severity of an existing condition. This capability is essential for personalized patient management.

• Blood Biomarkers for Prognosis:
  • C-reactive protein (CRP): Elevated CRP levels are recognized as a significant risk factor for AMD and are correlated with intermediate and advanced stages, thereby indicating its potential prognostic value for disease progression. 
  • High-density lipoprotein cholesterol (HDL-C): High levels of HDL-C have been identified as a risk factor for progression to late AMD. 
  • Vascular Endothelial Growth Factor (VEGF): Persistently elevated plasma VEGF levels are linked to disease progression, particularly to the more aggressive wet AMD form. 
  • Soluble FMS-like Tyrosine Kinase-1 (sFlt-1): Lower sFlt-1 levels are strongly associated with an increased risk of neovascular AMD (nvAMD), making it a promising prognostic biomarker for identifying individuals prone to developing this severe form. For patients over 73 years of age, sFlt-1 levels below 80 pg/ml were associated with a remarkable 6.7-fold increased risk of nvAMD. 
  • Genetic Markers: Genetic variants, such as those in Complement Factor H (CFH) and ARMS2/HTRA1, are crucial for predicting the risk of progression to advanced AMD. The development of polygenic risk scores, which integrate multiple genetic variants, is an ongoing effort to refine these prognostic predictions.
  • Red Blood Cell Distribution Width/Albumin Ratio (RAR): While specifically studied for AMD prevalence, RAR has demonstrated a crucial role in risk stratification and long-term prognosis prediction in other critically ill patient populations , suggesting analogous potential for AMD. 
• Urine Biomarkers for Prognosis:
  • Elevated urinary Macrophage Chemoattractant Protein-1 (MCP-1) levels have been associated with Geographic Atrophy (GA), suggesting its potential role in predicting the progression of this dry form of late AMD.   
  • The focus on prognostic biomarkers (CRP, HDL-C, VEGF, sFlt-1, genetic markers) indicates a shift from merely diagnosing AMD to predicting its trajectory for individual patients. This is crucial for personalized medicine, allowing clinicians to stratify patients into risk groups and tailor management strategies, potentially intensifying monitoring or initiating preventative measures for high-risk individuals before severe vision loss occurs. This moves beyond a static diagnosis to a dynamic, risk-informed approach to patient care.

C. Monitoring Disease Progression

Biomarkers can track the progress of a disease over time and provide valuable information for evaluating the effectiveness of therapeutic responses. 

• Blood Biomarkers for Monitoring:
  • Metabolomic Profiles: Plasma metabolomic profiles have been shown to vary with disease severity in AMD patients , suggesting that changes in these profiles could serve as indicators of disease progression. Metabolomics may offer new understandings for AMD monitoring.  
  • Circulating Autoantibodies: Elevated serum antibody ratios (IgG/IgM) against cyclic nucleotide phosphodiesterase phosphatidylserine (PS) have been strongly associated with various AMD stages, with these ratios increasing with advancing disease staging. This suggests their utility for monitoring disease progression. 
  • Red Blood Cell Distribution Width/Albumin Ratio (RAR): Its positive linear correlation with AMD prevalence suggests potential for monitoring disease activity or progression over time. 
• Urine Biomarkers for Monitoring:
  • The development of a urinary biomarker profile, including markers like TGF-β1 and MCP-1, could provide a practical and non-invasive tool for monitoring AMD progression. 
• Limitations: While these biomarkers show promise, their use for routine monitoring in clinical practice is largely confined to research settings at present.  
  • Monitoring disease progression requires biomarkers that change dynamically with disease activity or severity. The mention of metabolomic profiles varying with severity and autoantibody ratios increasing with staging indicates the search for such dynamic markers. This is vital for assessing the effectiveness of interventions in real-time and adjusting treatment plans, moving beyond static diagnostic snapshots to continuous disease management. 

D. Predicting Treatment Response

Biomarkers can play a pivotal role in evaluating the most effective therapeutic regimens for a particular disease type and predicting individual patient responses to interventions. This is a cornerstone of personalized medicine. 

• Blood Biomarkers for Predicting Treatment Response:
  • VEGF: While elevated VEGF is a marker of wet AMD, genetic single nucleotide polymorphisms (SNPs) within the VEGF gene can influence a patient's response to anti-VEGF therapies, guiding treatment decisions. 
  • MicroRNAs: Some miRNAs (e.g., miR-23, miR-27, miR-31, miR-150, miR-184, miR-126) have been shown to influence key processes such as angiogenesis and RPE protection. This suggests their potential as biomarkers to predict response to anti-angiogenic therapies or as direct therapeutic targets themselves
    
• Urine Biomarkers for Predicting Treatment Response:
  • A urinary biomarker profile, encompassing markers like TGF-β1 and MCP-1, could potentially provide a practical tool for assessing the efficacy of AMD treatments.
• Limitations: The translation of predictive biomarkers into routine clinical practice faces significant challenges, including variability in their performance and the necessity for large-scale, robust validation studies to confirm their utility. 
  • The concept of predicting treatment response is central to precision medicine. Identifying biomarkers that can forecast how a patient will respond to a specific therapy (e.g., anti-VEGF for wet AMD) can optimize treatment selection, avoid ineffective therapies, reduce side effects, and potentially improve patient outcomes. This moves beyond a "one-size-fits-all" approach to individualized treatment strategies, which represents a significant advancement in clinical care.

E. Biomarker Relevance Across AMD Stages

The utility and relevance of different biomarkers often change as AMD progresses through its distinct stages. A comprehensive approach to AMD management requires an understanding of these stage-specific biomarker profiles.

• Early AMD: This stage is characterized by stronger associations with lipid metabolism-related biomarkers, including Triglycerides (TG), HDL-C, ApoA1, and ApoB. This aligns with the understanding that drusen formation, a hallmark of early AMD, is fundamentally linked to lipid dysregulation. Inflammatory markers such as serum IP-10 and eotaxin are also significantly higher in early AMD. Additionally, urinary TGF-β1 and MCP-1 have shown associations with early AMD. 
• Intermediate AMD: This stage is particularly critical for identifying biomarkers that predict progression to late AMD. Structural biomarkers observed on Optical Coherence Tomography (OCT) are crucial here, including drusen volume, reticular pseudodrusen (RPD), pigmentary abnormalities, hyperreflective foci, and early signs of atrophy like incomplete RPE and outer retinal atrophy (iRORA) and nascent geographic atrophy (nGA).Functional markers such as Low-Luminance Visual Acuity (LLVA), microperimetry, dark adaptation (specifically Rod intercept time), and contrast sensitivity are often impaired in intermediate AMD. Among blood biomarkers, high HDL-C levels are recognized as a risk factor for progression to late AMD. 
• Late AMD (Dry/GA and Wet/nAMD): In the advanced stages, inflammatory processes become particularly pronounced. CRP's significance is more prominent in late AMD , and elevated IL-6 levels are significantly associated with late AMD (both GA and nAMD). For wet AMD, angiogenesis-related markers are key: elevated plasma VEGF levels are significantly higher , and lower sFlt-1 levels are strongly associated with nvAMD risk.Structural biomarkers, such as the presence and growth of exudation or atrophy on imaging, are directly associated with these late stages, where photoreceptor death and loss of best-corrected visual acuity (BCVA) have already occurred.
  • The clear stage-specific relevance of different biomarkers (e.g., lipid markers for early, inflammatory for late, OCT structural for intermediate/late) implies that a single "universal" AMD biomarker is unlikely to be sufficient for comprehensive management. Instead, dynamic biomarker panels, tailored to the patient's current disease stage and risk profile, would be more effective. This suggests a future where diagnostic and prognostic algorithms integrate multiple biomarker types, evolving as the disease progresses, to provide comprehensive and timely clinical guidance.

VI. Challenges, Limitations, and Inconsistencies in Biomarker Research

Despite significant advancements in identifying potential blood and urine biomarkers for AMD, their widespread clinical application is hindered by a complex array of challenges, limitations, and inconsistencies.

A. Translational Gap: From Research to Clinic

A substantial translational gap persists, meaning that despite promising research findings, no blood or urine biomarkers are currently used in routine clinical practice for screening, guiding management, or predicting outcomes or treatment response in AMD patients. This is not unique to AMD but represents a general challenge in biomarker development across various diseases. 

• Reasoning: The process of biomarker development and validation is financially burdensome and time-intensive, requiring rigorous intrinsic (analytical) and clinical validation. Analytical validation ensures the accuracy, precision, sensitivity, and specificity of the assay itself, while clinical validation determines its accuracy and efficacy in a real-world clinical setting. The most challenging and costly step is demonstrating that a biomarker test actually improves patient outcomes through controlled, randomized clinical trials, a process that can take years or even decades. Furthermore, any new biomarker must demonstrate a clear "clinical advantage" over existing diagnostic or prognostic methods in terms of cost, simplicity, accuracy, or rapidity, or address a previously unmet clinical need. 
  • The repeated emphasis on the lack of clinical implementation despite promising research points to a significant "translational gap" or "valley of death" between basic scientific discovery and clinical utility. This is not merely a technical problem but a systemic one, involving regulatory hurdles, funding challenges for large-scale trials, and the inherent complexity of proving real-world patient benefit. This suggests that future efforts need to focus heavily on robust clinical validation studies and economic feasibility to bridge this gap. 

B. Analytical Challenges: Specificity, Sensitivity, and Standardization

• Specificity and Sensitivity: Biomarkers must possess high sensitivity (the ability to correctly identify true positives, i.e., those with the condition) and high specificity (the ability to correctly identify those without the condition). However, there are often inherent trade-offs between sensitivity and specificity, and their optimal balance can vary significantly depending on the clinical context and the intended use of the test. Current diagnostic methods for kidney injury, such as serum creatinine and urine output, often lack sufficient sensitivity for early detection and can be influenced by non-renal factors like muscle mass, age, and sex. This broader challenge in kidney diagnostics highlights similar hurdles for AMD biomarkers, where achieving high sensitivity for early, subtle changes in AMD is crucial.  
• Standardization: A major impediment to the clinical translation of AMD biomarkers is the pervasive lack of standardized operating processes for sample collection, storage, and analysis. Inconsistencies in research results across different studies often stem directly from this variability in methodologies. Improper storage conditions, issues with collection equipment, and even transcription errors can significantly affect biomarker measurement accuracy. Standardization is also needed for the consistent definition of biomarkers (e.g., specific Tfh cell populations) and for assay protocols (e.g., IL-17+ T-cell frequency measurement). Without improved assay standardization, large-scale validation, and integration into clinical practice, the utility of these markers remains limited.  
  • The pervasive issue of "inconsistencies in the results indicating that standardized techniques would [be essential]" and the explicit mention of "lack of standardized operating processes" point to a fundamental challenge in biomarker research: reproducibility. Without standardized protocols for sample handling, measurement, and data analysis, comparing findings across different studies or laboratories becomes difficult, impeding validation and clinical translation. This implies a critical need for community-wide efforts to establish and adhere to rigorous methodological standards to ensure that research findings are reliable and comparable. 

C. Research Inconsistencies and Methodological Limitations

• Conflicting Data: Many potential biomarkers exhibit conflicting data regarding their association with AMD. Examples include the controversial link between elevated homocysteine levels and AMD, inconsistencies in cholesterol associations, and disparate findings regarding the influence of demographic factors like gender, iris color, obesity, and hypertension on AMD risk. Similarly, the association of certain genetic variants, such as ABCA4 mutations and FSCN2, with AMD has yielded conflicting results. 
• Small Cohort Sizes: A significant limitation in many biomarker studies is the reliance on small cohort sizes, which often leads to low statistical power. This can result in findings that are not robust or reproducible, contributing to the controversies observed in the field. 
• Bias and Confounding: Studies can be significantly affected by various biases and confounding factors. These include differential availability of biomarkers, issues with specimen acquisition and storage, and ascertainment procedures that differ between disease and control groups. Confounding factors, such as age, gender, diet, other metabolic conditions, and even variations in laboratory kits, can alter biomarker measurements and obscure true associations.  
• Complexity of Multi-factorial Disease: AMD's complex etiology, involving intricate interactions between numerous environmental and genetic risk factors, makes the identification of clear, singular biomarkers challenging. The observation that many individuals carrying known AMD-associated genes never develop the disease further indicates that other, yet-to-be-fully-understood factors are at play, complicating biomarker discovery. 
  • The prevalence of conflicting data, small cohort sizes, and unaddressed confounding factors suggests a significant "signal-to-noise" problem in AMD biomarker discovery. It is difficult to discern true biological associations from spurious correlations or methodological artifacts. This implies that future research must prioritize larger, well-designed, prospective studies with rigorous control for confounders and standardized methodologies to generate robust and reliable evidence that can withstand scrutiny and translate into clinical utility.

D. Regulatory and Economic Hurdles

• Financial Burden: The entire process of biomarker development and validation, from initial discovery to clinical implementation, is financially burdensome and highly time-intensive. This substantial investment is a major barrier for many research groups and smaller companies.
• Regulatory Approval: Biomarkers, like drugs, must undergo a multi-step process from initial identification through rigorous testing to eventual regulatory approval, a pathway that can span years or even decades. This stringent regulatory oversight, while necessary for patient safety, adds considerable time and cost to the development pipeline.
• Cost-Effectiveness: For genetic biomarkers, there is a critical need for the development of simple and inexpensive methodologies to make them accessible and widely applicable. The widespread use of new diagnostic tests, especially before conclusive evidence supporting their utility and cost-effectiveness is established, has the potential to cause harm to patients, widen health inequities by creating financial barriers to follow-up care, and further drive up healthcare costs.
  • The economic and regulatory hurdles (high cost, long timelines, the necessity to demonstrate a clear clinical advantage) represent a "commercialization bottleneck." Even scientifically sound biomarkers may fail to reach clinical practice if they cannot demonstrate sufficient economic viability or clear superiority over existing (even if imperfect) methods. This implies that future biomarker development must consider not only scientific rigor but also practical feasibility, cost-effectiveness, and clear pathways to regulatory approval and market adoption to ensure that promising discoveries can actually benefit patients. 
    
    

Table 3: Major Challenges in AMD Biomarker Translation

VII. Emerging Approaches and Future Directions

The landscape of AMD biomarker discovery is undergoing a transformative phase, driven by rapid advancements in high-throughput technologies and computational methods. These emerging approaches hold significant promise for overcoming current limitations and accelerating the translation of scientific discoveries into clinical practice.

A. Multi-omics Integration

• Concept: Multi-omics involves the simultaneous analysis and integration of data from multiple biological layers, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, and radiomics. This approach moves beyond studying individual biological components in isolation.
• Value: By considering multiple levels of a biological system concurrently, multi-omics offers a more comprehensive understanding of disease mechanisms, addressing the limitations of traditional diagnostic methods. This holistic view is critical for biomarker discovery, enabling earlier detection, personalized interventions, and ultimately improved patient outcomes. For instance, integrating genomics, transcriptomics, and proteomics data can provide a deeper understanding of the molecular characteristics of inflammatory bowel disease, a principle applicable to AMD.
  • The shift towards multi-omics signifies a move beyond reductionist approaches to a more holistic understanding of AMD. By integrating data from different biological layers, researchers can uncover complex interactions and feedback loops that contribute to disease, potentially identifying more robust and comprehensive biomarker signatures than single-omics approaches. This suggests that future biomarkers will likely be multi-dimensional, reflecting the intricate interplay of genetic, environmental, and metabolic factors that drive AMD pathogenesis.
• Challenges: Despite its potential, multi-omics integration faces significant challenges, particularly concerning data integration from disparate sources, standardization of methodologies across different omics platforms, and the rigorous clinical validation of identified multi-omics signatures. 

B. Liquid Biopsies

• Concept: Liquid biopsies represent a non-invasive method for analyzing biomarkers released by cells into various bodily fluids, including blood, urine, saliva, and cerebrospinal fluid. This approach offers a less invasive alternative to traditional tissue biopsies.  
• Types of Biomarkers: Liquid biopsies can detect a heterogeneous mixture of biomolecules, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs. These biomarkers provide insights into chromosomal abnormalities, gene mutations, and epigenetic changes. 
• Value: This technology offers significant promise for early disease detection, real-time disease monitoring, and evaluating treatment response. For instance, ctDNA analysis can capture real-time genomic alterations and serve as a sensitive indicator of treatment efficacy, allowing for timely adjustments to therapy and fostering personalized medicine.  
  • Liquid biopsies, particularly ctDNA, offer the promise of capturing "real-time genomic alterations" and providing a "more sensitive and specific indicator of treatment efficacy". This capability for dynamic, repeated, and non-invasive sampling is a transformative development for monitoring chronic diseases like AMD, allowing for timely adjustments to therapy and truly personalized treatment strategies. This suggests a future of continuous, adaptive patient management based on evolving biomarker profiles, moving beyond static diagnostic snapshots. 
• Challenges: Key challenges include molecular heterogeneity of biomarkers, the lack of assay standardization, and the effective integration of multiple biomarkers into routine clinical practice. The sensitivity of liquid biopsies can also be dependent on the "shedding" rate of biomarkers from the diseased cells, which can vary by disease type and progression. 

C. Artificial Intelligence (AI) and Machine Learning

• Role: Artificial intelligence (AI), encompassing machine learning (ML) and deep learning (DL), has emerged as a transformative tool in AMD research, with the potential to revolutionize both clinical practice and research methodologies. 
• Applications: AI-based algorithms excel at analyzing large and complex datasets, which is crucial for biomarker discovery and validation. Specific applications include precise and reproducible quantification of AMD biomarkers such as retinal fluid volumes, RPE atrophy, and photoreceptor integrity from imaging data. AI can also predict disease progression and stratify patients based on their likelihood of therapeutic response.Furthermore, AI can uncover novel biomarkers and refine the understanding of AMD pathophysiology. In clinical trial design, AI can optimize patient selection, enhancing statistical power and potentially reducing costs. AI can also streamline the collection and analysis of real-world data from electronic health records and other sources, playing a crucial role in biomarker development and validation by uncovering trends and outcomes. The predictive power of multi-omics technologies is expected to be further enhanced by leveraging AI and machine learning. 
  • AI's ability to process "large and complex datasets" and identify intricate patterns directly addresses the "signal-to-noise" problem inherent in biomarker discovery and the challenges of multi-omics integration. By rapidly identifying potential biomarkers and predicting their clinical utility, AI can significantly accelerate the discovery and validation pipeline, potentially overcoming some of the financial and time-intensive hurdles that currently limit biomarker translation. This suggests a future where AI acts as a powerful engine for biomarker development, enabling more efficient and targeted research. 

D. Collaborative and Standardized Research Initiatives

• Need for Collaboration: To overcome the pervasive inconsistencies and methodological limitations in biomarker research, multi-institutional, collaborative efforts are essential. These initiatives should focus on performing rigorously designed, prospective studies with serially enrolled patients, ensuring careful selection of controls and validation of selected biomarkers in independent cohorts. 
• Standardization: A critical need exists for standardized protocols to achieve consistent, reproducible results across different laboratories and studies, thereby facilitating direct comparisons of findings. Agreement on standardized validation procedures for automated analysis of AMD biomarkers, particularly from imaging data, would be of considerable translational value for clinicians and researchers. 
• Examples: The FDA's acceptance of a Qualification Plan for a urine biomarker panel for drug-induced kidney injury demonstrates a successful model of public-private partnership focused on standardization and clinical utility. Such collaborative initiatives, bringing together expertise from academia, industry, regulatory bodies, and advocacy organizations, are vital for advancing biomarker development.
  • The recurring theme of "inconsistencies" and "lack of standardization" underscores that biomarker development is not just about individual scientific breakthroughs but requires a collective, systemic approach. Collaborative initiatives and standardized methodologies are essential to build robust evidence, ensure reproducibility, and ultimately gain regulatory acceptance and clinical trust. This suggests that the future success of AMD biomarkers hinges on sustained, coordinated efforts across academia, industry, and regulatory bodies to establish and adhere to common research and validation standards. 

VIII. Conclusion

Significant progress has been made in identifying numerous blood and urine biomarkers associated with Age-related Macular Degeneration, reflecting its complex pathogenesis involving chronic inflammation, dysregulated lipid metabolism, and genetic predispositions. Specific markers, including C-reactive protein (CRP), various lipid profiles (Triglycerides, HDL-C, LDL-C, Apolipoproteins), Red Blood Cell Distribution Width/Albumin Ratio (RAR), Vascular Endothelial Growth Factor (VEGF), Soluble FMS-like Tyrosine Kinase-1 (sFlt-1), and certain microRNAs in blood, as well as Transforming Growth Factor-β1 (TGF-β1), Macrophage Chemoattractant Protein-1 (MCP-1), and some metabolites in urine, show promise for various clinical applications across early, intermediate, and late AMD stages. The varying relevance of these biomarkers across disease stages highlights the dynamic nature of AMD's pathophysiology, suggesting that different biological mechanisms may dominate at different points in disease progression.

Despite this progress, a substantial translational gap persists. No blood or urine biomarkers are currently in routine clinical use for AMD. This is due to a confluence of analytical challenges, including issues with specificity, sensitivity, and, most critically, a pervasive lack of standardization in research methodologies. Inconsistencies in research findings, often stemming from small cohort sizes and unaddressed confounding factors, further complicate the validation process. Additionally, significant regulatory and economic hurdles, including the high cost and time required for rigorous clinical validation and the need to demonstrate a clear clinical advantage, impede the widespread adoption of these promising discoveries.

The future of AMD biomarker discovery is dynamic and holds immense promise, driven by advancements in multi-omics integration, liquid biopsy technologies, and the transformative power of artificial intelligence. These approaches offer the potential to provide a more comprehensive understanding of AMD pathophysiology, identify multi-dimensional biomarker panels that capture the intricate interplay of disease mechanisms, and enable real-time, non-invasive monitoring of disease activity and treatment response. To overcome existing limitations and translate these scientific advancements into clinically actionable tools that can improve early detection, personalize treatment strategies, and ultimately preserve vision for millions affected by AMD, sustained collaborative and standardized research efforts across academic, industrial, and regulatory sectors will be crucial.

 

References: